BPC-157 vs TB-500 for injury: which one is built for your tear

One injury. One decision. You’ve narrowed the internet’s advice down to two vials — BPC-157 and TB-500 — and now you’re trying to work out which one to actually buy.

Here’s the good news the forums bury. The choice isn’t a coin toss. These two peptides do different jobs, and they point at different kinds of damage. Match the one to your tear and you’re at least reasoning the way the evidence would. Pick by whichever thread shouted loudest, and you’re guessing.

So let’s lay them side by side and sort out which is built for what. (If your real question is whether to run both together, that’s a separate trap with its own page — start here.)

Two repair tools, aimed at different damage

Start with the thing the sales pages blur: these two aren’t rival brands of the same product. They’re unrelated proteins that happen to share a shelf.

BPC-157 is a fifteen-residue fragment of a larger protein called body protection compound, first pulled from human gastric juice in the early 1990s by a Croatian group led by Predrag Sikirić. Its headline job is local. The 2025 Pharmaceuticals literature and patent review by Józwiak et al. catalogues the proposed activities, and the one injury circles care about is straightforward: grow new blood vessels into damaged tissue so the repair gets fed.

TB-500 points at something wider. The name refers to thymosin β4, a forty-three-amino-acid peptide your own cells already make, where it grabs actin and helps run the machinery that lets cells crawl toward damage and rebuild. That’s a whole-body repair signal, not a spot treatment.

Different molecules. Different jobs. That’s the fork in the road, and it’s worth taking seriously before you spend a penny.

What BPC-157 could do for a torn structure

Picture the injury BPC-157 built its reputation on: a specific tendon, a specific ligament, a joint that won’t settle down.

In rat studies, that’s exactly where it shines. Damage a tendon or ligament, give BPC-157, and the treated animals come back faster than the ones on saline. The proposed engine is easy to say out loud — more blood vessels into the injury, more blood means more repair delivered to the exact spot. A 2025 systematic review in orthopaedic sports medicine frames it as an emerging candidate across tendon, ligament, and bone. A 2026 review goes narrower, looking at it alongside growth factors at the junctions where tendon and muscle anchor into bone — the spots that take longest to come back.

So if your problem has an address — this tendon, that ligament — BPC-157 is the tool aimed most directly at it. That’s the genuinely exciting part. If the rat signal holds in people, it’s pointed at precisely the thing you tore.

Now the boundary, kept short. Almost all of that record is rats, and almost all of it traces to one research group across three decades. Heavy, consistent, single-lineage. It hasn’t had the outside-lab scrutiny you’d want before you bet your own shoulder on it.

What TB-500 could do across the whole repair job

TB-500 sells a broader promise, and the biology under it is genuinely interesting.

Its parent protein, thymosin β4, is one of the signals your body uses to move cells toward damage and switch repair on — across a lot of tissues at once. Philp and Kleinman’s 2010 review is the foundational sweep: animal studies in skin wounds, corneal scrapes, and heart-attack tissue, all showing faster, better-organised repair with less scar. The appeal isn’t one target. It’s breadth — a systemic get-the-repair-crews-moving signal.

There’s a second reason the biology tempts people. Inside the body, Tβ4 breaks down into a short fragment called Ac-SDKP, and Wang and colleagues (2022) review how that fragment pushes back against fibrosis in liver, kidney, heart, and lung models. Anti-fibrotic is the right direction for healing. A lot of injuries recover badly precisely because scar tissue lays down in a disorganised mess.

Here’s the catch, and it’s specific to TB-500. What’s in the vial often isn’t the protein the research is on. The published work is mostly on full-length Tβ4 — all forty-three residues. The grey-market product is frequently a seven-residue piece (the LKKTETQ fragment) or Ac-SDKP itself. Same label, different molecule. So even the animal evidence may not describe what you’d actually be injecting.

And the tendon column is nearly bare. The single tendon-adjacent paper is Wu and colleagues (2020), who loaded Tβ4 onto a synthetic scaffold built to mimic tendon and watched human stem cells migrate and switch on tendon genes. Careful work. But it’s cells on a piece of plastic in a dish — no animal, no human, no actual tendon.

The spec sheet

Line the two up on the boring facts first, because the marketing sands them flat into two recovery peptides when they’re nothing of the sort.

Two things jump off that sheet. The FDA isn’t reviewing the same use for each one. And the which TB-500 is this problem is real — a paper reporting that TB-500 did something can mean three different molecules, depending on what was in the syringe.

The human file, side by side

Here’s where the two stop looking comparable at all.

For BPC-157, the human record is thin but not empty. There’s a two-person intravenous safety pilot by Lee and Burgess (PMID 40131143) with no efficacy endpoint, and a registered Phase 1 pharmacokinetic study (NCT02637284) that never posted results. Then, new this year, the first controlled trial in an actual injury indication: NCT07437547, a Phase 2 randomised placebo-controlled study of BPC-157 for acute hamstring strain, recruiting now. No read-out yet — but it exists.

For TB-500, the human file for tendon repair is a blank page. Not a Phase 1. Not a registered controlled trial. Not a published case series. The 2026 Sports Medicine review by Mendias and Awan names both peptides in its list of approved and unapproved compounds where rigorous human safety data is scarce and the market runs largely outside regulatory oversight.

The split is stark. BPC-157 has a thin human file with one injury trial finally pointed at it. TB-500 has none for the thing people buy it to fix.

So which one for which injury

Strip out the anecdote and the choice mostly sorts itself by what you’ve actually done to yourself.

Torn or strained a specific structure — a tendon, a ligament, a joint gone sour? BPC-157 is the more directly-aimed tool. Its animal record sits squarely on that kind of damage, and it’s the only one of the two with a human injury trial recruiting right now. That study won’t read out for a while. But it’s the first time anyone has asked the question properly.

After broad, systemic recovery, or a soft-tissue wound rather than one tendon? That’s closer to where Tβ4’s parent biology actually earned its animal record. The honest snag is that the human proof is thinner still, and you can’t be sure the vial holds the molecule those studies used.

Gut trouble tilts the same way as tendon, oddly. BPC-157 is the one born from gastric-mucosa research, and its PCAC indication is a gut condition. TB-500’s isn’t.

So the plain version. For a specific torn structure, BPC-157 carries the more injury-pointed evidence and the only human trial. For broad tissue repair, TB-500’s biology is wider but the proof underneath is shakier and the molecule murkier. Neither has proof it repairs a human injury yet. One is finally being tested. The other hasn’t started.

Where the regulators put them

The two peptides land in the same room exactly once, and it’s a federal one.

Both BPC-157 and TB-500 are on the FDA Pharmacy Compounding Advisory Committee’s July 23, 2026 docket, per the April 2026 Federal Register notice. The indications the FDA is actually reviewing aren’t the ones the forums buy them for. BPC-157 is under review for ulcerative colitis — a gut condition. TB-500 is under review for wound healing — broader, but still not tendon repair.

PCAC is advisory. It recommends; the FDA decides later through rulemaking. What that review can and can’t open is its own story, and the mechanics live in what a PCAC review actually is. The short version for a choice like this: even a favourable vote wouldn’t bless injecting either peptide into a torn tendon. It would open a narrow, supervised, prescription lane for the listed indication, and nothing wider.

For competition, both sit on the wrong side of the line. BPC-157 is WADA-prohibited at all times. TB-500 falls under S2 — growth factors and related substances — also prohibited in and out of competition. If you’re tested, neither is a grey area.

What about running both

The obvious next thought is to stop choosing and take both.

That’s a genuinely different question, and it carries its own trap: nobody has ever tested the two together in an injury. We pulled that pitch apart on its own page — is the Wolverine Stack actually a stack? Read it before you assume two half-answers add up to a whole one.

When the version worth choosing exists

So the real decision isn’t quite BPC-157 or TB-500.

It’s between guessing which vial matches your injury off a forum thread, and having someone who saw the actual scan tell you. Right now only the guessing option is on the shelf. That’s the part we’re trying to fix.

Wolverine Health is building the version that doesn’t run on faith — physician-supervised peptide protocols, US-licensed compounding pharmacies, every batch third-party tested, in the indications and dose forms the regulation actually clears. It isn’t live yet, and we won’t pretend it is. The July 23 PCAC meeting decides much of what’s even possible, and we’d rather tell you what it landed on than what we’re hoping for. Leave your email, and we’ll come back to you the day picking the right one stops being a guess.